Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Slides:



Advertisements
Similar presentations
Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan  Yoshio Taguchi, Masahito.
Advertisements

Pulmonary response in sarcoidosis
Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.
Pathological alterations in idiopathic pulmonary fibrosis (IPF).
Changes in high-resolution computed tomography (HRCT) pattern over time. a) Idiopathic pulmonary fibrosis (IPF), increased specificity over time. Changes.
Flow diagram of the systematic research method for detecting matching microRNAs (miRNAs) in systemic sclerosis (SSc) and idiopathic pulmonary fibrosis.
H. Grasemann, E. Tullis, F. Ratjen  Journal of Cystic Fibrosis 
Disease progression is preceded by right ventricular remodelling, but not by changes in clinical parameters. Disease progression is preceded by right ventricular.
High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.
Radiology assessment of pulmonary amyloidosis
Schematic representation of the potential clinical courses of idiopathic pulmonary fibrosis. Schematic representation of the potential clinical courses.
The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.
Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.
Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.
Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.
Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.
Changes of a) spirometric, plethysmographic, and b) impedance data at 5 Hz induced by bronchodilator in flow limited (□) and nonflow limited (▓) patients.
Exploratory pooled analysis (studies 004 and 006 combined) of a) categorical forced vital capacity change at week 72 and b) 6-min walk test distance decrement.
Axial computed tomography (CT) images a) at baseline and b) at a 12-month follow-up scan, in a patient with idiopathic pulmonary fibrosis (IPF). b) Note.
Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.
Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.
Changes in operating lung volumes are shown as ventilation increases with exercise in a) age-matched normal subjects (n = 25) and b) chronic obstructive.
Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)
Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.
Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––)
Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.
Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.
Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.
3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).
Evaluation of acute symptoms
Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating.
Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.
Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.
The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.
Evaluation of complications.
Forest plot comparison of mucolytics versus placebo for the number of exacerbations per patient per month. Forest plot comparison of mucolytics versus.
Elastic staining of paraffin-embedded lung tissue.
Post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio in subjects aged >50 yrs. Post-bronchodilator forced expiratory.
Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.
Proteinase activated receptor-1 expression in a) weak immunostaining in normal lung tissue, b) intense immunostaining in idiopathic pulmonary fibrosis,
A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.
Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;
Right ventricular (RV) pressure–volume loops at decreasing venous return in a patient with a) systemic sclerosis-associated pulmonary arterial hypertension.
Exertional dyspnoea intensity is shown relative to a) work rate and b) diaphragm electromyography relative to maximum (EMGdi/EMGdi,max) during incremental.
The alveolar compartment in idiopathic pulmonary fibrosis (IPF).
Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.
Effects of N-acetylcysteine (▒) and placebo (░) on vital capacity (VC) and diffusing capacity of the lung for carbon monoxide (DL,CO) depending on baseline.
This schematic view of the morpho-functional unit of the lung (alveolus) depicts the main differences in cellular composition in idiopathic pulmonary fibrosis.
Change in physiological variables from baseline values a) at rest and b) during exercise after saline infusion and exposition to different β-blocker agents.
The effect of inhaled tiotropium (18 μg once daily) on the improvement in treadmill exercise endurance time in patients with chronic obstructive pulmonary.
Kaplan–Meier survival curves for baseline cardiac magnetic resonance imaging variables according to the median value in patients with pulmonary hypertension.
Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.
Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)
Proportion of participants with access to a, b) a radiologist and c, d) a pathologist experienced in interstitial lung diseases to discuss cases of suspected.
Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s
Comorbidities/associated conditions/complications assessed in patients diagnosed with idiopathic pulmonary fibrosis (IPF) in the 2013 Advancing IPF Research.
Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.
Distribution of systolic pulmonary artery pressure (Ppa) in relation to functional class (FC) for congenital heart disease patients with a) atrial septal.
Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study.
Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.
Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )
Clinical findings in patients with chronic obstructive pulmonary disease according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Distribution of diffusing capacity of the lung for carbon monoxide (DLCO) among 243 scleroderma patients who underwent right heart catheterisation (RHC)
Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.
Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:
Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.
Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF).
Real-life pulmonary arterial hypertension (PAH) patient cases to reflect the importance of a collaborative approach to patient engagement. Real-life pulmonary.
Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.
Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.
Presentation transcript:

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1) or placebo in patients with idiopathic pulmonary fibrosis (IPF). Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1) or placebo in patients with idiopathic pulmonary fibrosis (IPF). CAPACITY: Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes. Reproduced from [23]. Jürgen Behr Eur Respir Rev 2013;22:163-168 ©2013 by European Respiratory Society